Drugs / Cefadroxil
Cefadroxil
also known as
Anhydrous cefadroxil · Baxan · BL-S578 · Cefadrops · Cefadroxil (as monohydrate) · Cefadroxil anhydrous · Cefadroxil hydrate · Cefadroxil monohydrate · +8 more
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | DURICEF | — | 1991-08-30 | fda.gov ↗ |
| Approved | US (FDA) | DURICEF | — | 1978-02-17 | fda.gov ↗ |
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials · 2 met primary | ||||||
| Phase 1 | NCT03802552 | May 2019 → Apr 2021 | bacterial arthritis, osteomyelitis, pyomyositis | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1 | NCT02140281 | May → Aug 2014 | — | Ardelyx | Completed | No outcome recorded |
| Phase 1 | NCT00834275 | Sep → Oct 2004 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1 | NCT00835081 | Sep → Oct 2004 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 23 trials | ||||||
| Phase 2 | NCT06406114 | May 2025 → Jul 2028 expected | anaphylaxis, drug allergy, drug pseudoallergy | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT02381470 | Feb → Sep 2019 | pulmonary tuberculosis | National University Hospital, Singapore | Completed | No outcome recorded |
| Phase 2 | NCT00332163 | Apr 2006 → Jan 2008 | colorectal cancer, exanthem, toxic dermatosis | Amgen | Completed | No outcome recorded |
| Phase 42 trials · 1 met primary | ||||||
| Phase 4 | NCT07561541 | Apr 2026 → Dec 2027 expected | diabetes mellitus | Texas Tech University Health Sciences Center, El Paso | Recruiting | No outcome recorded |
| Phase 4 | NCT01244698 | Nov 2010 → May 2014 | bacterial infectious disease | Stony Brook University | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT04631185 | May 2021 → Dec 2023 | — | The Plastic Surgery Foundation | Completed | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 3 | NCT04723940 Comparator | Jan 2021 → Jan 2028 expected | periprosthetic joint infection | Rothman Institute Orthopaedics | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT02814916 Comparator | Mar 2017 → Jan 2024 | methicillin-resistant staphylococcus aureus infectious disease | AbbVie | Completed | No outcome recorded |
| Phase 4 | NCT05977868 Background | Aug 2023 → Feb 2025 | digestive system infectious disorder | West Virginia University | Terminated | No outcome recorded |
| Phase 4 | NCT04297592 Comparator | Jun 2020 → Jan 2027 expected | autoimmune disease, chronic kidney disease, diabetes mellitus, methicillin-resistant staphylococcus aureus infectious disease +3 | Mayo Clinic | Enrolling by invitation | No outcome recorded |
| — | NCT00405158 Background | Jan 2002 → Mar 2004 | mastitis | Karlstad University | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2013-02-13 | Sobi, Inc. | Sobi gains distribution rights for Megace®, Monopril®, Cefzil® and Duricef® from PharmaSwiss sobi.com ↗ |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cefadroxil | “oral antibiotic (eg, doxycycline, ciprofloxacin, cefadroxil, amoxicillin/clavulanic acid), topical steroid (hydrocortisone cream), topical antibiotic (clindamycin), oral...” NCT00332163 ↗ |
| Known as | Anhydrous cefadroxil | ChEMBL registry synonym — accepted as the source's own label CHEMBL1644 ↗ |
| Known as | Baxan | ChEMBL registry synonym — accepted as the source's own label CHEMBL1644 ↗ |
| Known as | BL-S578 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1644 ↗ |
| Known as | Cefadrops | ChEMBL registry synonym — accepted as the source's own label CHEMBL1644 ↗ |
| Known as | Cefadroxil (as monohydrate) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1644 ↗ |
| Known as | Cefadroxil anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL1644 ↗ |
| Known as | Cefadroxil hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1644 ↗ |
| Known as | Cefadroxil monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1644 ↗ |
| Known as | Cefadroxil/cefadroxil hemihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1644 ↗ |
| Known as | Cefadroxilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL1644 ↗ |
| Known as | Cefatabs | ChEMBL registry synonym — accepted as the source's own label CHEMBL1644 ↗ |
| Known as | Duracef | ChEMBL registry synonym — accepted as the source's own label CHEMBL1644 ↗ |
| Known as | Duricef | “The patients will be prescribed one week of Cephalosporin Antibiotic (Keflex/Duricef/Other) of their surgeon's choice.” NCT04631185 ↗ |
| Known as | MJF 11567-3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1644 ↗ |
| Known as | NSC-756664 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1644 ↗ |
| Known as | Ultracef | ChEMBL registry synonym — accepted as the source's own label CHEMBL1644 ↗ |
| Modality | Small molecule | “cefadroxil (a first generation cephalosporin)” NCT02381470 ↗ |
| Route | Oral | “The control group will receive oral outpatient Cefadroxil (500mg 2 times a day) until the final drain is removed.” NCT01244698 ↗ |